Affordable Access

Access to the full text

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

  • Rini, Brian I.1
  • Battle, Dena2
  • Figlin, Robert A.3
  • George, Daniel J.4
  • Hammers, Hans5
  • Hutson, Tom6
  • Jonasch, Eric7
  • Joseph, Richard W.8
  • McDermott, David F.9
  • Motzer, Robert J.10
  • Pal, Sumanta K.11
  • Pantuck, Allan J.12
  • Quinn, David I.13
  • Seery, Virginia9
  • Voss, Martin H.10
  • Wood, Christopher G.7
  • Wood, Laura S.1
  • Atkins, Michael B.14
  • 1 Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA , Cleveland (United States)
  • 2 KCCure, Leesburg, VA, USA , Leesburg (United States)
  • 3 Cedars-Sinai Medical Center, Los Angeles, CA, USA , Los Angeles (United States)
  • 4 Duke University School of Medicine, Durham, NC, USA , Durham (United States)
  • 5 UT Southwestern, Dallas, TX, USA , Dallas (United States)
  • 6 Charles A. Sammons Cancer Center, Baylor, Dallas, TX, USA , Dallas (United States)
  • 7 MD Anderson Cancer Center, Houston, TX, USA , Houston (United States)
  • 8 Mayo Clinic, Jacksonville, FL, USA , Jacksonville (United States)
  • 9 Beth Israel Deaconess Medical Center, Boston, MA, USA , Boston (United States)
  • 10 Memorial Sloan-Kettering Cancer Center, New York, NY, USA , New York (United States)
  • 11 City of Hope, Duarte, CA, USA , Duarte (United States)
  • 12 UCLA School of Medicine, Los Angeles, CA, USA , Los Angeles (United States)
  • 13 Norris Comprehensive Cancer Center, Los Angeles, CA, USA , Los Angeles (United States)
  • 14 Georgetown, Lombardi Comprehensive Cancer Center, Research Building, Room E501 3970 Reservoir Road NW, Washington, DC, 20057, USA , Washington (United States)
Published Article
Journal for ImmunoTherapy of Cancer
Springer (Biomed Central Ltd.)
Publication Date
Dec 20, 2019
DOI: 10.1186/s40425-019-0813-8
Springer Nature


The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as monotherapy in 2015 for aRCC after treatment with a VEGF-targeting agent. In April 2018, the combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, was approved for intermediate- and poor-risk, previously untreated patients with aRCC. Then, in 2019, combinations therapies consisting of pembrolizumab (anti-PD-1) or avelumab (anti-PD-ligand (L) 1) with axitinib (a VEGF receptor tyrosine kinase inhibitor) were also approved to treat aRCC and are likely to produce dramatic shifts in the therapeutic landscape. To address the rapid advances in immunotherapy options for patients with aRCC, the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease.

Report this publication


Seen <100 times